| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1998;66:337-346
© 1998 The Society of Thoracic Surgeons
a Divisions of Cardiothoracic Surgery and Pulmonary Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
Address reprint requests to Dr Egan, University of North Carolina at Chapel Hill, 108 Burnett-Womack Bldg, CB 7065, Chapel Hill, NC 27599-7065
Presented at the Forty-fourth Annual Meeting of the Southern Thoracic Surgical Society, Naples, FL, Nov 6–8, 1997.
Background. The purpose of this study was to review our experience with lung transplantation in patients with end-stage cystic fibrosis.
Methods. Eight-two patients with cystic fibrosis have undergone bilateral lung transplantation (n = 76) or bilateral lower lobe transplantation (n = 6) since October 1990.
Results. Actuarial survival for the entire cohort is 79% at 1 year and 57% at 5 years. The development of bronchiolitis obliterans syndrome is the leading cause of death after the first year. Freedom from bronchiolitis obliterans syndrome is 84% at 1 year and 51% at 3 years. Pulmonary function tests improve dramatically in recipients. There was no association between death within 1 year and recipient age, weight, graft ischemic time, cytomegalovirus seronegativity, or the presence of panresistant organisms. Similarly, there was no association between the development of bronchiolitis obliterans syndrome within 2 years and ischemic time, number of rejection episodes, cytomegalovirus seronegativity, or the presence of panresistant organisms.
Conclusions. Despite their poor nutritional status and the presence of multiply resistant organisms, patients with cystic fibrosis can undergo bilateral lung transplantation with acceptable morbidity and mortality.
This article has been cited by other articles:
|
|
 |
|
  W Chalermskulrat, N Sood, I P Neuringer, T M Hecker, L Chang, M P Rivera, L J Paradowski, and R M Aris Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation Thorax, June 1, 2006; 61(6): 507 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Reed General thoracic surgery and the Southern Thoracic Surgical Association: the second 25 years Ann. Thorac. Surg., November 1, 2003; 76(90050): S14 - 16. [Full Text] [PDF]
|
|
|
|
 |
|
 T.M. Egan, F.C. Detterbeck, M.R. Mill, M.S. Bleiweis, R. Aris, L. Paradowski, G. Retsch-Bogart, and B.S. Mueller Long term results of lung transplantation for cystic fibrosis Eur. J. Cardiothorac. Surg., October 1, 2002; 22(4): 602 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Vricella, J. M. Karamichalis, S. Ahmad, R. C. Robbins, R. I. Whyte, and B. A. Reitz Lung and heart-lung transplantation in patients with end-stage cystic fibrosis: the stanford experience Ann. Thorac. Surg., July 1, 2002; 74(1): 13 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. ARIS, J. C. ROUTH, J. J. LIPUMA, D. G. HEATH, and P. H. GILLIGAN Lung Transplantation for Cystic Fibrosis Patients with Burkholderia cepacia Complex . Survival Linked to Genomovar Type Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2102 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Date, M. Yamashita, I. Nagahiro, M. Aoe, A. Andou, and N. Shimizu Living-donor lobar lung transplantation for primary ciliary dyskinesia Ann. Thorac. Surg., June 1, 2001; 71(6): 2008 - 2009. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
